All In Biotech

NDA 220358 · Vanda Pharms INC

Bysanti

Milsaperidone · Oral

Novel

CDER novel approval, Feb 20, 2026: To treat schizophrenia and to treat manic or mixed episodes associated with bipolar I disorder

Last checked: Nov 19, 2026Latest source record: Feb 20, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2026

Feb 20, 2026

Approved uses

1

Original approval plus efficacy supplements

Registered trials

1

1 Phase 3, 1 recruiting

FAERS reports

0

0 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. BYSANTI is not approved for the treatment of patients with dementia-related psychosis [see Warnings and Precautions (5.1) ] . WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. BYSANTI is not approved for use in patients with dementia-related psychosis. ( 5.1 )

What it is approved for

From the label in effect Feb 27, 2026.

BYSANTI ™ is indicated for the: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ] . Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . BYSANTI is an atypical antipsychotic indicated for: Treatment of schizophrenia in adults. ( 1 , 14.1 ) Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults. ( 1 , 14.2 )

Mechanism: The mechanism of action of milsaperidone in the treatment of schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults is unknown. However, the efficacy of milsaperidone in these conditions could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Milsaperidone and iloperidone rapidly interconvert in vivo. Milsaperidone has an in vitro receptor binding profile similar to iloperidone.

Therapeutic areas: Psychiatry

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Feb 20, 2026 Original approval · Type 1 - New Molecular Entity NovelLetterLabelReview
7 products under this application
  • BYSANTI · MILSAPERIDONE 4MG · TABLET, ORAL · Prescription
  • BYSANTI · MILSAPERIDONE 1MG · TABLET, ORAL · Prescription
  • BYSANTI · MILSAPERIDONE 10MG · TABLET, ORAL · Prescription
  • BYSANTI · MILSAPERIDONE 6MG · TABLET, ORAL · Prescription
  • BYSANTI · MILSAPERIDONE 2MG · TABLET, ORAL · Prescription
  • BYSANTI · MILSAPERIDONE 12MG · TABLET, ORAL · Prescription
  • BYSANTI · MILSAPERIDONE 8MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Milsaperidone" as an intervention, any sponsor and status, largest first.

All 1 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals

No FAERS reports name this application.

FAERS reports by year

By the date FDA received the report.

No reports.

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 0 on PubMed

No PubMed clinical studies matched.

Sponsor: Vanda Pharms INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.